Achaogen Inc. to Post FY2016 Earnings of ($2.36) Per Share, William Blair Forecasts (AKAO)
Achaogen Inc. (NASDAQ:AKAO) – Equities research analysts at William Blair reduced their FY2016 earnings per share (EPS) estimates for shares of Achaogen in a report issued on Monday. William Blair analyst Y. Xu now forecasts that the brokerage will earn ($2.36) per share for the year, down from their prior forecast of ($2.15). William Blair also issued estimates for Achaogen’s Q4 2016 earnings at ($0.50) EPS and FY2017 earnings at ($2.31) EPS.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.20. The firm had revenue of $16.05 million for the quarter, compared to the consensus estimate of $8.72 million. Achaogen had a negative net margin of 147.80% and a negative return on equity of 143.44%. The company’s revenue for the quarter was up 258.3% on a year-over-year basis. During the same period last year, the firm posted ($0.48) earnings per share.
Other equities analysts have also recently issued reports about the stock. Wedbush reissued an “outperform” rating and issued a $10.00 price objective on shares of Achaogen in a research note on Tuesday. Zacks Investment Research raised shares of Achaogen from a “sell” rating to a “hold” rating in a research note on Thursday, August 25th. Needham & Company LLC reissued a “hold” rating on shares of Achaogen in a research note on Tuesday, August 9th. Aegis assumed coverage on shares of Achaogen in a research note on Wednesday, November 2nd. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Cowen and Company reissued a “hold” rating on shares of Achaogen in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $8.63.
Achaogen (NASDAQ:AKAO) opened at 4.89 on Thursday. Achaogen has a 1-year low of $2.59 and a 1-year high of $6.18. The stock’s market capitalization is $130.46 million. The stock has a 50 day moving average of $4.77 and a 200 day moving average of $4.02.
Several institutional investors have recently bought and sold shares of AKAO. Northern Trust Corp boosted its position in Achaogen by 52.6% in the third quarter. Northern Trust Corp now owns 23,346 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 8,046 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in Achaogen by 13.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 85,472 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 10,330 shares during the period. Eagle Global Advisors LLC boosted its position in Achaogen by 55.4% in the second quarter. Eagle Global Advisors LLC now owns 38,749 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 13,812 shares during the period. ICONIQ Capital LLC boosted its position in Achaogen by 100.3% in the second quarter. ICONIQ Capital LLC now owns 28,629 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 14,333 shares during the period. Finally, Bridgeway Capital Management Inc. boosted its position in Achaogen by 13.2% in the second quarter. Bridgeway Capital Management Inc. now owns 156,185 shares of the biopharmaceutical company’s stock worth $592,000 after buying an additional 18,235 shares during the period. 56.83% of the stock is currently owned by institutional investors and hedge funds.
Achaogen Company Profile
Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).
Receive News & Stock Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related stocks with our FREE daily email newsletter.